Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04791319 · ClinicalTrials.gov registry record · Phase 2
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT04791319 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 199 participants.
The verdict
NCT04791319, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG Bermekimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04791319
The ClinicalTrials.gov registry entry for NCT04791319 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04791319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04791319 about?
NCT04791319 is a clinical study titled "A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis". The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT04791319?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2021-05-03. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04791319?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), Bermekimab (DRUG).
Who is sponsoring clinical trial NCT04791319?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.